Article Text
Abstract
Objectives The GIOVE Study was aimed to the achievement of allocative efficiency of the budget allocated to the prevention of human papillomavirus (HPV)-induced diseases. An ex-ante determination of the most efficient allocation of resources between screening and multicohort quadrivalent immunisation programmes was followed by the ex-post assessment of the allocative efficiency actually achieved after a 12-month period.
Design A bound optimisation model was developed to determine the ex-ante allocative efficiency of resources. The alternatives compared were the screening programme alone and the quadrivalent immunisation with access to screening. A sensitivity analysis was carried out to assess the uncertainty associated with the main inputs of the model. Subsequently, a cohort of girls with a complete recorded vaccination history were enrolled in an observational retrospective study for 18 months to ensure full compliance with the recommended schedule of vaccination (0, 2, 6 months) within a 12-month time horizon.
Setting Basilicata region, in the south of Italy.
Participants 12 848 girls aged 12, 15, 18 or 25 years.
Intervention Immunisation with quadrivalent anti-HPV vaccine.
Outcome measures The vaccination coverage rate was considered to be the indicator of the best achievable benefit, given the budgetary constraints.
Results Assuming a vaccine price of €100 per dose, a vaccination coverage rate of 59.6% was required for the most effective allocation of resources. The optimal rate of coverage was initially in favour of the multicohort strategy of vaccination against HPV (72.8%±2%). When the price paid for the quadrivalent vaccine dropped to €85 per dose, the most efficient coverage rate (69.5%) shifted closer to the immunisation rate actually achieved during the 12-month observation period.
Conclusions The bound optimisation model demonstrated to be a useful approach to the ex-ante allocation and the ex-post assessment of the resources allocated to the implementation of a multicohort quadrivalent anti-HPV vaccination programme.
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.
Statistics from Altmetric.com
Footnotes
To cite: Mennini FS, Baio G, Montagano G, et al. Governance of preventive Health Intervention and On time Verification of its Efficiency: the GIOVE Study. BMJ Open 2012;2:e000736. doi:10.1136/bmjopen-2011-000736
Contributors FSM, GF and AC: conception and design, drafting the article and final approval of the version to be published. GB, AM, LG and GB: analysis and interpretation of data, revising it critically for important intellectual content and final approval of the version to be published. PZ, GM, GC, FL: conception and design, revising it critically for important intellectual content and final approval of the version to be published.
Funding This work was supported with an unrestricted funding from Sanofi Pasteur MSD, Italy.
Competing interests None.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement There is no additional data available.